Ferroptosis {#S1}
===========

Ferroptosis is a recently identified type of regulated cell death ([@B30]). Specifically, it is a non-apoptotic, iron-dependent, oxidative cell death mechanism that was proposed by [@B31]. Ferroptosis, which is classified as "cell sabotage" ([@B49]), differs from apoptosis, necrosis, and autophagy in terms of morphology, biochemistry, and heredity ([@B18]). Ferroptosis is mainly characterized glutathione (GSH) consumption and lipid peroxidation, which involves specific oxidation of phosphatidylethanolamine containing arachidonic and adrenal acids ([@B27]). The following unique gene set is required for erastin-induced ferroptosis: ribosomal protein L8, iron response element-binding protein 2, F0-F1-ATPase subunit C3, citrate synthase, tetratricopeptide repeat domain 35, and acetyl-CoA synthetase family member ([@B102]).

Ferroptosis is studied through step-wise *in vivo* and *in vitro* experiments using various activators and inhibitors ([@B117]). Previous cell experiments ([@B31]; [@B123]; [@B34]) have shown that ferroptosis is triggered by the oncogenic RAS-selective lethal small molecule erastin, RAS-selective lethal 3, buthionine sulfoximine and sulfasalazine. Ferroptosis induced by the aforementioned compounds and drugs has been detected in cancer cells ([@B121]), kidney tubule cells ([@B41]), neurons ([@B51]), and T cells ([@B76]). Consequently, there are various types of ferroptosis inhibitors with different targets including iron chelators ([@B111]), antioxidants ([@B31]), ferrostatins-1 (Fer-1) ([@B97]), glutathione peroxidase 4 (GPX4) ([@B123]), hypoxia-inducible factor prolyl hydroxylase inhibitors ([@B102]) and other Chinese medicine ([@B4]). Trials on these drugs have shown that the ferroptosis mechanism involve lipid reactive oxygen species (ROS) production, plasma membrane polyunsaturated fatty acid (PUFA) oxidation, iron metabolism, and antioxidant GSH metabolism ([@B111]; [@B61]; [@B115]). Notably, ferroptosis is not cell suicide; rather it involves cell sabotage that occurs normal life activities to adapt to stimuli and body changes ([@B49]; [@B30]). Therefore, ferroptosis is only observed in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity ([@B117]), when it is misregulated or unbalanced where it induces other cell death mechanisms and immunoreactions ([@B113]; [@B75]; [@B82]).

Ferroptosis plays an important role in the brain and neurological diseases ([@B67]). The brain has the highest levels of PUFAs, which are recognized as lipid peroxide precursors, in the human body ([@B11]). Moreover, there is a close to correlation of GSH depletion and lipid peroxidation with neurological diseases, including neurotrauma, stroke, and neurodegeneration ([@B10]; [@B112]). Studies have reported an increase in the ferroptosis phosphatidylethanolamine (PE) marker after traumatic brain injury (TBI) ([@B116]). Moreover, cellular ferroptosis has been observed in dopaminergic neurons in Parkinson's disease (PD) and other neurodegenerative diseases ([@B34]). Similarly, ferroptosis inhibitors, including Fer-1 and liproxstatin-1 (Lip-1), have been shown to significantly reduce functional deficits in ischemic stroke mouse models. This indicates that ferroptosis is involved in stroke and ischemia-reperfusion injury ([@B107]). Further, GPX4 genetic defects have been observed in *in vivo* and *in vitro* neuronal death ([@B127]; [@B20]). Taken together, ferroptosis is a potential therapeutic target for neurological diseases given the complexity and fine regulation of the central nervous system (CNS), as well as the unclear changes in neurological diseases.

The targeted ferroptotic mechanism depends on the pathogenesis of the neurological disease; however, lipid peroxidation is generally regarded as the driving force of ferroptosis ([@B124]). Hence, we first introduce lipid peroxidation followed by a summary of the main ferroptotic mechanisms and drugs targeting ferroptosis to treat neurodegenerative diseases, stroke, and brain trauma.

Lipid Peroxidation Is the Driving Force of Ferroptosis {#S2}
======================================================

Lipid peroxidation products are recognized as the most potent inducers of ferroptosis ([@B61]). Lipid peroxide biosynthesis can be performed by enzymes, including 12/15-lipoxygenase (12/15-LOX) and 5-lipoxygenase (5-LOX), or through non-enzymatic processes known as Fenton-type chemistry ([@B45]). Lipid peroxidation is preferential for PUFAs, which are long-chain fatty acids with more than one double bond, including linoleic, arachidonic, and docosahexaenoic acids. They are highly enriched in the brain where they increase membrane fluidity and plasticity to promote neurotransmitter release and neural network development and migration ([@B45]; [@B57]).

Lipid peroxidation is inhibited by GPX enzymes, especially GPX4, which reduces phospholipid hydroperoxide to lipid alcohols ([@B14]) and restricts the formation of reactive lipid alkoxy groups ([@B91]). Lipid peroxide-induced ferroptosis involves the following three steps shown in [Figure 1](#F1){ref-type="fig"}. First, as a key regulator, acyl-CoA synthetase long-chain family member 4 (ACSL4) catalyzes the esterification of arachidonoyl (AA) or adrenoyl (AdA) into PE. Second, lysophosphatidylcholine acyltransferase 3 (LPCAT3) is specific for PE-based substrates and generates PUFA-PE. Finally, 15-LOX oxidizes AA-PE and AdA-PE into ferroptotic signals, including PE-AdA-OOH and PE-AA-OH ([@B27]). For high lipid peroxide levels, lipid peroxide aggregates have been reported in the endoplasmic reticulum ([@B36]). Moreover, other studies have shown that lipid peroxidation accumulation on the mitochondrial membrane is a key factor for ferroptosis ([@B41]; [@B69]). Here, CRISPR-based genome-wide genetic screening and microarray analysis have demonstrated ACSL4 and LPCAT3 as key ferroptosis regulators ([@B33]; [@B36]). Notably, GPX4 depletion induces ferroptosis only when ACSL4 and LPCAT3 are expressed and involved in arachidonic acid modification with subsequent insertion into membrane phospholipids ([@B22]; [@B95]). Downstream events of lipid peroxides include PUFA fragmentation and membrane lipid damage, as well as toxic reactive lipid intermediate 4-hydroxynonenal production. This leads to cellular ferroptosis promotion through covalent modification and inactivation of essential intracellular proteins ([@B90]).

![The related ferroptosis mechanisms in neurological diseases. The drugs with red box are ferroptosis inducer and the drugs with green box are ferroptosis inhibitor. AA, arachidonic acid; AdA, adrenic acid; ACSL4, acyl-CoA synthetase long-chain family member 4; AOA, amino acetate; α-KG, α ketoglutarate; BSO, buthionine sulfoximine; 2,2-BP, 2,2-bipyridyl; β-ME, β-mercaptoethanol; CO, carbon monoxide; CoQ 10, Coenzyme Q10; CP, ceruloplasmin; DMT1, divalent metal transporter 1; FAC, ferric citrate; FINO2, 1, 2-dioxolane; FSP-1, Ferroptosis-suppressor-protein 1; GCL, glutamate cysteine ligase; GLS2, glutaminase 2; Glu, glutamate; GSS, glutathione synthetase; GSSG, oxidized GSH; Hb, hemoglobin; HIF, hypoxia-inducible factor; 4-HNE, 4-hydroxynonenal; HO-1, heme oxygenase 1; Lip-1, liproxstatin-1; LPCAT3, lysophosphatidylcholine acyltransferase 3; NAA, neutral amino acids; NAC, N-acetylcysteine; NOX, nitrogen oxide; 2-OG, 2-oxoglutarate; PPP, pentose phosphate pathway; RSL3, RAS-selective lethal 3; SAS, sulfasalazine; STEAP3, 6-transmembrane epithelial antigen of the prostate 3.](fncel-14-00218-g001){#F1}

Studies using erastin have shown that system Xc^--^, which is a transmembrane cystine/glutamate reverse transporter, plays an important role in ferroptosis ([@B31]). System Xc^--^ is comprised of the 12-pass transmembrane transporter SLC7A11 ([@B89]), which promotes cysteine-dependent GSH synthesis ([@B31]). The following steps lead to ferroptosis. First, erastin inhibits system Xc^--^ and competitively inhibits cystine uptake, which leads to cysteine depletion (the rate-limiting precursor for GSH synthesis). Subsequently, this causes GSH depletion, which leads to imbalanced cellular oxidants and antioxidants, and oxidative, which induces cell death ([@B96]; [Figure 1](#F1){ref-type="fig"}). Furthermore, A Gln- and citrate synthase-dependent lipid synthesis pathway can supply specific lipid precursors required for ferroptosis ([@B31]).

Ferroptosis in Neurodegeneration {#S3}
================================

The Ferroptosis Mechanism in Neurodegeneration: Free Iron Accumulation {#S3.SS1}
----------------------------------------------------------------------

Neurodegenerative diseases include complex and elaborate cell death mechanisms and multiple pathways, which involve excessive accumulation of iron and lipid peroxidation in different brain regions ([@B51]). An important feature of nervous system dysfunction is the metabolic and nutritional coupling between glial cells (astroglial cells, oligodendrocytes, and microglia) and neurons, which can lead to neuronal death, especially in ferroptosis ([@B86]). Ferroptosis is dependent on excessive iron accumulation, which is a crucial component of lipid oxidation and is derived from iron metabolism disorder ([@B18]). Under normal CNS conditions, iron is mainly combined with ferritin and neuromelanin. Iron, which is an important cofactor in the CNS ([@B77]), participates in several important processes, including oxygen transportation, oxidative phosphorylation, myelin production, and neurotransmitter synthesis and metabolism ([@B111]). Through the transferrin-transferrin receptor 1 (TF-TFR1) system, iron is released into the cytoplasmic after crossing the blood-brain barrier. Subsequently, it continuously moves among neurons, oligodendrocytes, and astrocytes. The inactive iron (Fe^3+^) form is recognized by TF and moved into the cell by TFR1. Subsequently, Fe^3+^ is converted into free iron (Fe^2+^) by 6-transmembrane epithelial antigen of the prostate 3 (STEAP3) ([@B65]; [@B116]). Free iron is transported by divalent metal transporter 1 (DMT1) from the endosome and exported by ferroportin. Free iron can be stored in ferritin or the labile iron pool with the latter being involved in lipid ROS generation. Fe^2+^ is a cofactor for metalloenzymes in many oxidation reactions, including those modulated by lipoxygenase and hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) ([@B64]; [@B61]; [@B122]). Further, free iron can be released to the labile iron pool by lysosomes, which degrade ferritin via nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy ([@B106]). Therefore, brain iron homeostasis is maintained through the regulation of iron movement between blood and brain tissue; intracellular and extracellular; and among different iron pools ([@B65]; [@B44]). Protein-bound iron is safe; contrastingly, abnormal iron homeostasis involving excessive free iron generates molecules that can destroy proteins and nucleotides through Fenton chemical reactions, which leads to lipid peroxidation ([@B65]; [@B116]). Therefore, iron is intricately involved in the onset and progression of neurodegenerative diseases ([@B96]; [@B111]). The involvement of excessive iron accumulation in neurodegenerative diseases includes oxidative stress induction, mitochondrial function interference, excessive ROS production, and destruction of nuclear DNA and mitochondria ([@B65]). Daniel I [@B80] have shown that in neurodegenerative diseases, pantothenate kinase-associated neurodegeneration may disrupt lipid homeostasis, change the mitochondrial iron-dependent biosynthetic pathway and cytoplasmic iron homeostasis and produce harmful ROS. Moreover, iron accumulation in neurodegenerative diseases could involve gene mutations related to iron transport and binding, changes in the TF transport system, increased divalent metal transporter 1 expression ([@B19]), and blood-brain barrier dysfunction ([@B111]; [Figure 1](#F1){ref-type="fig"}).

Ferroptosis Inhibitors in PD {#S3.SS2}
----------------------------

### Ferroptosis Induction by Excess Iron in PD {#S3.SS2.SSS1}

PD is characterized by neuronal loss in multiple brain regions, especially dopaminergic neurons in the substantia nigra. Moreover, the causative factor of PD is α-synuclein protein ([@B51]). Based on these PD traits, the key treatment target is restoring brain dopamine levels and preventing neuron degeneration. Iron-dependent ferroptosis is a crucial cell death pathway for dopaminergic neurons ([@B34]). In PD, dopaminergic neurons have abundant iron, which is an integral part of enzymatic and non-enzymatic reactions involved in dopamine metabolism ([@B77]). In addition, free iron induces dopamine oxidation and α-synuclein aggregation ([@B37]) which leads to increased dopaminergic neuron loss in PD; moreover, it mutates TF and causes excessive iron uptake ([@B111]). The possible underlying mechanism could involve excess free iron being able to reduce GPX4 activity, which, in turn, leads to GSH depletion. Subsequently, there is a reduced ROS clearance ability of cells, which leads to excessive ROS, membrane oxidation, and eventual ferroptosis ([@B56]; [@B103]; [@B110]). Moreover, α-synuclein oligomers significantly increase the rate of active oxygen production, and induce lipid peroxidation and the increase of iron-dependent free radicals in neurons and astrocytes, such aggregates will be incorporated into the cell membrane through mutual action leading to ferroptosis, which may play an important role in the cellular mechanism of neuronal cell loss in Parkinson's disease ([@B6], [@B5]). Experiments show that PUFA is more resistant to lipid peroxidation through site-specific deuteration, which can prevent α-Syn-induced lipid peroxidation and α-Syn-induced cell death ([@B6]).

### Iron Chelators in PD {#S3.SS2.SSS2}

Iron chelators are ferroptosis inhibitors, that target free iron in labile iron pools and prevent iron from supplying electrons to oxygen to form ROS ([@B32]). There are two categories of iron chelators, membrane-permeable (lipophilic iron chelators), and membrane-impermeable ([@B18]). Lipophilic iron chelators, which include ciclopirox and 2,2-bipyridyl, penetrate the cell membrane and blood-brain barrier, target iron accumulation areas, and remove chelatable iron from labile iron pools or transport it to other proteins ([@B13]). For ferroptosis inhibition, lipophilic iron chelators prevent PUFA fragment oxidation and lipid ROS formation ([@B43]). Moreover, lipophilic iron chelators can directly inactivate ferrous enzymes that promote membrane lipid oxidation ([@B18]), as well as hypoxia-inducible factor-prolyl hydroxylases ([@B96]). This exerts neuroprotective effects by simulating hypoxia, stabilizing HIF-1α, and activating hypoxia-adaptive genetic programs ([@B64]). In contrast, membrane-impermeable iron chelators include deferoxamine (DFO) and deferiprone (DFP), which accumulates in lysosomes through endocytosis from where they capture excess free iron ([@B9]).

Numerous *in vivo* and *in vitro* experiments have shown that iron chelators play an essential role in PD ([@B34]). DFP reduces oxidative stress, increases cellular dopamine utilization, improves existing motor symptom, and prevents worsening in MPTP mouse models ([@B26]). A phase III clinical trial on iron chelators treatment in patients with PD reported reduced dyskinesia and increased GSH peroxide activity in the cerebrospinal fluid within 6 months ([@B51]; [@B74]). Notably, most patients with neurodegenerative disease present normal systemic iron homeostasis during iron chelators application ([@B111]). Excessive systemic iron chelation therapy is unsuitable for patients with PD and may cause iatrogenic iron depletion and anemia. Therefore, low-dose iron chelation therapy should be used to allow neuroprotective effects with minimal side effects ([@B77]). A novel strategy based on iron clearance and redeployment targets has been proposed to allow targeted and differential specificity ([@B17]). A study conducted by [@B26] administered 30 mg/10 g/day DFP to patients with PD. Clinical benefits were observed at 6 months, dyskinesia was significantly reduced at 12 months, and a normal iron index was restored at 18--24 months. This indicated that a lower DFP dose was safe with a risk for reversible neutropenia of 1--3% ([@B26]). Moreover, a study by [@B128] reported that ferroptosis occurred at a relatively low ferric citrate concentration, while apoptosis occurred with an increase in the iron dose. This is indicative of the role of early death in PD and shows that ferroptosis can result in apoptosis caused by iron overload. Furthermore, the specific ferroptosis inhibitor Fer-1 and the iron chelator DFO inhibit iron-induced cell death and apoptosis in the early PD stages ([@B128]). In addition, a recent study shows that in the rodent Parkinson's disease model, Clioquinol has the effect of an iron chelator. By reducing the iron content in substantia nigra, it inhibits the production of lipid peroxides and ferroptosis, and produce a therapeutic effect ([@B94]).

Ferroptosis Inhibitors in Alzheimer's Disease (AD) {#S3.SS3}
--------------------------------------------------

### The Relationship Between Ferroptosis and AD {#S3.SS3.SSS1}

AD is characterized by progressive cortical and hippocampal neuronal dysfunction and death. Its main pathological changes include hyperphosphorylation, abnormal Tau aggregation, and synapses and neurons degeneration ([@B38]; [@B87]); synapses are lost and neuronal death is the underlying AD cause ([@B52]). Ferroptosis characteristics (iron dysregulation, lipid peroxidation, and inflammation) are considered as important preclinical signs of AD and cognitive impairment ([@B20]; [@B52]). Lipid peroxidation is considered an early event in AD pathogenesis ([@B53]). Specifically, excess iron aggravates toxic amyloid β peptide and hyperphosphorylated tau aggregation; moreover, it directly induces oxidative neuronal damage ([@B105]). Iron interacts with amyloid β and tau through peptide-heme complex formation, and thus contributes to ROS generation, which might be involved in the ferroptosis pathway ([@B25]). Moreover, brain tissues from patients with AD have increased levels of 4-hydroxynonenal, a lipid oxidation by-product, which contributes to β-amyloid accumulation ([@B126]).

### Lipid Peroxidation Inhibitors in AD {#S3.SS3.SSS2}

A study by [@B129] reported that an AD mouse model with Tau overexpression and hyperphosphorylation presented with excess iron. Studies have proposed treatment with α-lipoic acid (LA), which has natural enzyme cofactors with antioxidants and iron chelator properties; moreover, it easily penetrates the blood-brain barrier. LA administration has been shown to down-regulate TFR expression and up-regulate ferroportin 1expression, which reduces the iron overload. LA regulates iron redistribution through iron chelation; moreover, it acts as a direct free radical scavenger and an indirect antioxidant. Therefore, it reduces ROS levels and increases antioxidant enzymes expressions (GPX4 and Xc^--^) to play the neuroprotective role in AD ([@B81]). Furthermore, GPX4-knockout mice present cognitive impairment and neurodegenerative changes, which are associated with lipid peroxidation, extracellular signal-regulated kinase activation, and markedly increased neuroinflammation ([@B52]). Therefore, GPX4 protects cortical neurons from oxidative damage and amyloid toxicity ([@B85]; [@B126]). Notably, hydroxylated chalcone inhibits Aβ aggregation and ferroptosis by exerting a pharmacological effect on factors for iron-induced death (including GPX4 or Xc^--^ inhibition); therefore, it could be a candidate treatment for AD ([@B24]).

Others {#S3.SS4}
------

[@B12] used synthetic lethal CRISPR/Cas9 screening technology, and the results showed that myristoylation recruited ferroptosis-suppressor-protein 1(FSP1) to the plasma membrane, which acts as an oxidoreductase, reducing coenzyme Q10, producing a lipophilic free radical trapping antioxidant to prevent the spread of lipid peroxides. The FSP1-CoQ 10 -NAD(P)H pathway exists as an independent parallel system and can be used in conjunction with GPX4 and glutathione to inhibit phospholipid peroxidation and ferroptosis ([@B12]; [@B35]). Virus-inactivated and heat-treated human platelet lysate has a strong neuroprotective effect against erastin-induced ferroptosis ([@B79]) and has been developed as a novel and effective neurodegenerative therapy. Human platelet lysates can inhibit ferroptosis and reduce neuronal loss in cellular models of PD and amyotrophic lateral sclerosis (ALS) ([@B47]). Third, as another type of inhibitor, Mithramycin, DNA-binding drugs, can reduce c-Myc expression by binding to the Sp1 site in its promoter, thereby playing a role in inhibiting iron death and treating animal models of HD and AD ([@B98]; [@B86]). Fourth, in mouse hippocampal neuron cells, gastrodin inhibits glutamate-induced ferroptosis through the Nrf2/HO-1 signaling pathway ([@B60]). Besides, Nrf-2 activators (such as Tecfidera) are now used in clinical applications to reduce the exacerbation of multiple sclerosis involving ferroptosis and see hope in other neurodegenerative diseases ([@B92]). Fifth, it is worth noting that diacetyl-bis (4-methyl-3-thiosemicarbazonato) copper II \[Cu II (atsm)\], by inhibiting ferroptosis, delays the progression of ALS and PD. Compared with lipoxstatin-1 (which has similar potency *in vitro*), Cu II has better properties including oral bioavailability and entry into the brain ([@B101]). Moreover, Vitamin E/α-tocopherol could act as a 12/15-LOX inhibitor in neurodegenerative diseases ([@B76]). Finally, it was also found that the transglutaminase inhibitor Cystamine can eliminate glutamate-induced ferroptosis ([@B39]) and the histone deacetylase inhibitor PCI-34051 is an effective neuroprotection and has a role in preventing neuronal ferroptosis ([@B99]).

Ferroptosis in Stroke {#S4}
=====================

Ferroptosis in Ischemic Stroke {#S4.SS1}
------------------------------

### The Mechanism of Ferroptosis in Ischemic Stroke {#S4.SS1.SSS1}

Hypoxia-inducible factor prolyl hydroxylases (HIF-PHD) is considered as a neuroprotective target for "antioxidant" metal chelators. PHD, which is the main oxygen sensor, promotes HIF decomposition and inhibition during the normoxic state. However, PHD inhibition during the hypoxia condition maintains HIF stability ([@B64]). On the one hand, HIF-PHD is involved in iron-chelator-related mechanism. Specifically, iron chelator inhibits HIF-PHD activity, which inhibits hydroxyl group production. Consequently, unhydroxylated HIF-1α does not bind ubiquitin-protein ligase and is not degraded. As a result, the \[HIF-1α\]-\[HIF-1β\] heterodimer activates protective gene expression, including vascular endothelial growth factor and erythropoietin. This exerts further neuroprotective effects and improves acute stroke recovery ([@B93]; [@B15]; [@B96]). On the other hand, the possible process of HIF-PHD causing ferroptosis is as follows: when glutathione is depleted, iron released from the disruption of the glutathione-Grx3/Grx4 Fe/S cluster complex could then be taken up into iron chaperones (PCB1) for enzymes such as the HIF PHDs, and then drive the expression of iron-promoting ATF4 gene, thereby causing ferroptosis ([@B86]).

### Ferroptosis Inhibitors in Ischemic Stroke {#S4.SS1.SSS2}

Ischemic stroke is characterized by rapid neuronal death and dysfunction. Moreover, post-ischemic stroke complications cause further neuronal damage. Therefore, there is a need for further research to further improve stroke prevention and treatment ([@B107]). HIF-PHD inhibitors have been shown to reduce neuronal damage caused by permanent focal ischemia and can be clinically used as neuroprotective agents in cases with an imminent risk of ischemic or oxidative neuron damage ([@B96]). In addition, dimethyloxalylglycine significantly reduced the infarct volumes and improved behavior at 24 h and 8 days. Moreover, it improved regional cerebral blood flow after 24 h in a rat model with permanent and transient middle cerebral artery occlusion ([@B78]).

A feasible strategy for first-line stroke treatment 12/15-LOX is inhibition using LOXBlock-1, which protects neuronal HT22 cells from oxidative stress. In a mouse model of transient focal ischemia, LOXBlock-1 reduced the infarct size and improved behavioral parameters at both 24 h and 14 days after stroke. This protective effect was observed even with delayed treatment until at least 4 h after the ischemic attack. Additionally, since LOXBlock-1 showed no adverse effects in the collagenase-induced bleeding model, it could be used as an adjuvant for tissue plasminogen activator thrombolysis ([@B125]). Notably, intraperitoneal Tat Selpep injection to induce GPX4 expression can reduce the post-focal ischemia infarct size. Moreover, in the mouse ischemic model, it drives the transcription reaction to offset reactive lipid formation and cell death, as well as improves important nerve function within clinically relevant time windows ([@B2]). Intranasal Lip-1/Fer-1 administration to middle cerebral artery occlusion mice significantly alleviated MCAO-induced functional defects and reduced the infarct size after 14 days ([@B107]). Analysis of the drug structure indicated that "amines" are essential for inhibition of cellular ferroptosis; further, Fer-1 analog synthesis can develop more efficient ferroptosis inhibitors, including SRS11-92, SRS12-45, etc. ([@B97]).

Ferroptosis in Hemorrhagic Stroke {#S4.SS2}
---------------------------------

### The Mechanism of Ferroptosis in Hemorrhagic Stroke {#S4.SS2.SSS1}

Post-hemorrhagic stroke damage is triggered by red blood cells lysis; hemoglobin, heme, and iron release; and coagulation cascade activation. This leads to irreversible destruction of neurovascular unit components with subsequent blood-brain barrier destruction, extensive neuronal death, and fatal brain edema ([@B83]; [@B66]; [@B131]). After intracranial hemorrhage ([@B44]), heme is degraded by heme-oxygenase into carbon monoxide, biliverdin, and free iron, which induces ferroptosis ([@B116]; [Figure 1](#F1){ref-type="fig"}).

### Ferroptosis Inhibitors in Hemorrhagic Stroke {#S4.SS2.SSS2}

In the hemorrhagic stroke model, Tat Selpep effectively drives GPX4 expression in the brain, protects and protect neurons, and improves behavior ([@B2]). Adaptaquin reduces cell death and enhances functional recovery in intracerebral hemorrhage (ICH) rodent models ([@B62]). Through toxic lipids neutralizations, the synergistic effect of clinically approved thiol-containing redox-regulating N-acetylcysteine and prostaglandins E inhibits heme-induced ferroptosis and improve the prognosis of hemorrhagic stroke in mice ([@B63]).

Others {#S4.SS3}
------

Naotaifang reduces TFR1 expression, ROS and iron accumulation, and neurobehavioral scores in a rat model of acute cerebral artery occlusion ([@B70]). Moreover, Carvacrol reduces the tissue lipid peroxide levels to protect gerbils from ischemia-reperfusion injury ([@B50]).

Ferroptosis in Neurotrauma {#S5}
==========================

The Mechanism of Ferroptosis in Neurotrauma {#S5.SS1}
-------------------------------------------

Post-TBI cell death is a cause of neurological deficits and death ([@B104]; [@B7]). After brain trauma, there is overexpression of lipid peroxidase, including cyclooxygenase and LOX. One of the earliest mechanical injury events is excessive free fatty acid release. There was a significant increase in free fatty acids in the brain within 5 min after TBI, which remained high at 24 h after the injury ([@B28]). There is a post-TBI increase in the biomarkers of iron-induced death. Further, LOX inhibition in ferroptosis can protect HT22 neurons from *in vitro* TBI and promote tissue neuroprotection and PE oxidation after control cortex injury ([@B67]). Therefore, ferroptosis prevention in brain trauma strengthens the defense system, removes oxidized membrane lipids, prevents 15LOX/PEBP1 complex formation, and reduces the membrane lipid dioxide oxidation rate ([@B7]).

Ferroptosis Inhibitors in Neurotrauma {#S5.SS2}
-------------------------------------

First, the PEBP1/15LOX complex in cortical and hippocampal neurons is a potential treatment target for brain trauma. This is based on the balance between 15-LOX-produced PE-PUFA-OOH metabolites and GPX4 reduction to hydroxyl metabolites in ferroptosis ([@B113]). Therefore, specific inhibitors targeting the PEBP1/15-LOX complex could serve as a novel treatment strategy for ferroptosis ([@B58]). Similarly, Baicalein inhibits ferroptosis and improves post-TBI behavioral outcomes ([@B4]; [@B67]). Additionally, N-acetylcysteine has a protective effect on GSH in adult, but not pediatric, patients with TBI ([@B3]; [@B54]).

Differences and Relationships Among Various Cell Death Mechanisms in Neurological Diseases ([Table 1](#T1){ref-type="table"}) {#S6}
=============================================================================================================================

Different cell death mechanisms, apoptosis, necrosis, autophagy and ferroptosis occur in neurological diseases ([@B51]). Each mechanism has typical morphology, regulators, and inhibitors ([Table 1](#T1){ref-type="table"}). Assessment of intracellular proteases in neurological diseases by [@B120] indicated that neuronal cell death is induced by the generation of ROS, including H~2~O~2~; increased intracellular calcium levels; activation proteases (caspase, calpain, cathepsin), and inactivation/activation of kinases.

###### 

Differences and relationships among various cell death mechanisms in neurological diseases.

  **Cell death**          **Differences**   **Relationships**                                                                                                                                                                                                                                                                                                                               
  ----------------------- ----------------- --------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Programmed cell death   Apoptosis         cell shrinkage, plasma membrane blebbing, karyorrhexis, chromatin condensation, and DNA fragmentation     Caspase Bax, Bak AIF 1 P53   Bcl-2                                       PD ([@B51]) Stroke (apoptosis in the penumbra) ([@B120]) AD ([@B100]) ASL ([@B40]) HD ([@B46])   Cleared by macrophages or other phagocytic cells ([@B82])   Biochemical substances related to ferroptosis metabolism inhibit the execution of apoptosis ([@B30]).
                          Ferroptosis       Atrophy of mitochondria rounded-up cell body and changed mitochondrial morphology and cristae structure   Fe Lipid ROS                 Iron chelators, GPX4, Fer-1, Lip-1, FSP-1   PD ([@B51]) AD ([@B24]) HD ([@B97]) Stroke ([@B132]) Neurotrauma ([@B54])                        Immunogenicity                                              Ferroptosis in neurological diseases induced by different targets.
                          Autophagy         Autophagosome, double membrane vesicle formation                                                          Calpain Atg LAMP2            3-MA                                        PD ([@B51]) ICH ([@B132]) Stroke ([@B1]) ALS ([@B16]) HD ([@B46])                                N/A                                                         NCOA4-mediated ferritinophagy is an autophagic phenomenon which induce ferroptosis by degradation of ferritin.
  Accidental cell death   Necrosis          Swelling of cytoplasm and organelles, karyolysis and disruption of plasma membrane                        Cathepsin RIP1 RIP3          Nec-1                                       PD ([@B51]) Stroke (necrosis in the core of the injury) ([@B23]) ICH ([@B72])                    Immunogenicity                                              Ferroptosis may be a regulator of necrotic cell death ([@B75]).

AIF1, apoptosis-inducing factor 1; Atg, autophagy-related genes; 3-MA, 3-methyladenine; Nec-1, necrostatin-1; RIP, receptor interacting protein.

First, the morphological characteristics of apoptotic neuron cells include cell shrinkage, plasma membrane blebbing, karyorrhexis, chromatin condensation, and DNA fragmentation. Apoptosis, which is a common programmed cell death mechanism, has been demonstrated in the penumbra of patients with stroke ([@B120]) and neurodegenerative diseases, including PD, AD ([@B100]), ALS ([@B40]), and Huntington disease (HD) ([@B46]). Further, patients with PD present with elevated levels of proapoptotic protein Bax and activated caspase in dopaminergic neurons ([@B51]). *In vitro* cell experiments have shown that caspase-activated upstream apoptotic mechanisms are not involved in cellular ferroptosis; moreover, GSH-depleted cells cannot properly activate caspase ([@B31]). Accordingly, [@B30] suggested that ferroptosis-related biochemical substances inhibit apoptosis.

Second, necrosis is characterized by the swelling of cytoplasm and organelles, karyolysis and plasma membrane disruption in collagenase-induced mouse ICH models observable using transmission electron microscope ([@B72]). Necrosis, which refers to accidental cell death ([@B120]), is observed in early stage stroke injury ([@B23]). In addition, necroststin-1, the necrosis inhibitor, reduces the toxicity of 6-hydroxydopamine (6-OHDA) in the PD model ([@B51]). Ferroptosis may be a regulator of necrotic cell death ([@B82]); specifically, it may induce secondary upregulation of necrotic mechanical components and exacerbate tissue damage ([@B75]).

Third, autophagy has been observed in neurological diseases. Three days after ICH, autophagosome and double-membrane vesicle formation have been observed in the mouse ICH model ([@B72]). Moreover, the morphological characteristics of autophagy have been observed in patients with PD ([@B51]). In adult mice with carotid artery occlusion and hypoxia, stroke causes reperfusion deficits and autophagic/lysosomal cell death in the brain ([@B1]). In addition, autophagosomes appear in the neurons of patients with ALS ([@B16]) and HD ([@B46]). Notably, it induces ferroptosis, which leads to ferritinophagy ([@B109]). NCOA4-mediated ferritinophagy is an autophagic phenomenon that induces ferroptosis via ferritin degradation ([@B55]). Under ferroptotic conditions, ferritin is degraded by autophagy, which preserves the labile iron pool and makes the cell more sensitive to ferroptosis ([@B42]). Further, autophagy may share key regulators with ferroptosis ([@B88]).

Taken together, the relationship among apoptosis, necrosis, autophagy and ferroptosis is delicate and complex in neuronal and surrounding glial cells, with each mechanism having its corresponding time windows. In addition, cell death forms vary across different brain regions with different neuronal sensitivity. For example, the ventral region is more sensitive to PD neurodegeneration in the substantia nigra area ([@B51]). In addition, given that pathology caused by tissue damage and degeneration is related to inflammation, the immune response and involved cells could be used to distinguish among the different cell death mechanisms ([@B48]). Apoptotic cells are cleared by macrophages or other phagocytic cells based on the plasma membrane integrity ([@B82]). Contrastingly, in necroptosis and ferroptosis, the release of damage-associated molecular patterns through the ruptured plasma membrane triggers the innate immune system in brain tissues with high immunogenicity ([@B30]; [@B82]). Regarding therapy, Fer-1 combined with different cell death inhibitors allows better prevention of hemoglobin-induced cell death in organotypic hippocampal slice cultures and human pluripotent stem cell-derived neurons than any of the inhibitors alone. In a collagenase-induced mouse ICH model, a combination of Fer-1, caspase3 inhibitor, and necrostatin-1 can reduce cell death more than any of the inhibitors alone ([@B71]).

Summary {#S7}
=======

The related ferroptosis mechanisms in neurological diseases are summarized in [Figure 1](#F1){ref-type="fig"} and the recent drugs that target ferroptosis for neurological disease treatment are summarized in [Table 2](#T2){ref-type="table"}. There are several prospects regarding ferroptosis in the nervous system. First, there is a need for chemical probes or biomarkers capable of elucidating the ferroptosis mechanism to determine its role in the nervous system given the quick cell death occurrence and difficulty in obtaining appropriate neurons ([@B51]). In contrast with other cell death mechanisms, mitochondrial atrophy ([@B132]), as well as immunity-related cells and factors ([@B82]), may be potential markers. Moreover, cyclooxygenase ([@B71]) and lipid peroxides can be assessed as potential chemical probes or biomarkers ([@B30]; [@B103]). It is showed in the latest report that nanoparticles with adjustable size, charge, and targeting ligands show high specificity for the brain, which may provide a reference for the design of new anti- ferroptotic nanomedicines in the future ([@B119]). Second, since ferroptosis is a cell sabotage mechanism, it should be assessed as a potential adaptive change in the body's response to stimuli ([@B30]). Third, redox phosphatidyl liposomes in the ferroptosis process involve, PE- and PUFA-PEox as substrates and redox reactions products and catalytic or regulatory proteins, such as 15-LOX, PEBP1, and GPX4. The interactions among these liposome components could elucidate relevant pathogeneses and they could be assessed as potential targets for drug therapy ([@B113]). Fourth, the use of LOXBlock-1 with tissue plasminogen activator significantly reduces bleeding, which suggests that this combination could be a useful treatment strategy for ischemic stroke. Further research is required to determine whether simultaneous administration is required, as well as the appropriate time window ([@B125]). Fifth, while assessing the role of the various ferroptosis inhibitors, attention should be paid to the combined use of other cell deaths inhibitors and different drug delivery methods.

###### 

Potential drugs that target ferroptosis for neurological disease treatment.

  **Ferroptosis inhibitors**   **Neurotrauma**                                      **Stroke**                                                                                                                                                         **Neurodegeneration**                                                                                                                                                                                                                                                                                            
  ---------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------ -----------------
  Iron chelators               N/A                                                  DFO ([@B112])                                                                                                                                                      DFP ([@B21]) Clioquinol ([@B94])                                                                   PBT2 ([@B111])                                             N/A                                                                                                                                                
  Lipid ROS Inhibitors         XJB-5-131 ([@B59]) Luteolin ([@B118]) NAC ([@B54])   Lip-1 ([@B107]) Fer-1 ([@B71]) NAC ([@B68]) Baicalein ([@B108]) ML351 (Inhibitor of 12/15-LOX) ([@B84]) Trolox ([@B132]) LOXBlock-1 ([@B125]) Tat Selpep ([@B2])   GPX4 ([@B130]) Tat Selpep ([@B2]) N-acetylcysteine (NAC) ([@B63]) Fer-1 ([@B71]) Ebselen ([@B8])   GPX4 ([@B20]) FSP1 ([@B21]) Cu II ([@B101])                Hydroxylated Chalcones ([@B24]) GPX4 ([@B126]) PD146176 (Inhibitor of 12/15-LOX) ([@B29]) α-Lipoic Acid ([@B129])   NAC ([@B114]) Fer-1 ([@B97])   Cu II ([@B101])
                                                                                                                                                                                                                                                                                                                                                          Lip-1 ([@B52]) Fer-1 ([@B97]) Mithramycin ([@B86])                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                          XJB-5-131 ([@B69]) CoQ10 ([@B112]) Tecfidera ([@B92])                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                          Radical trapping antioxidant ([@B73]) Gastrodin ([@B60])                                                                                                                                                      
  HIF-PHD inhibitors           N/A                                                  peptide HIF prolyl 4-hydroxylase inhibitors ([@B96]) Dimethyloxalylglycine (DMOG) ([@B78]) DHB ([@B64])                                                            Adaptaquin ([@B62]) Hypoxia-inducible factor prolyl hydroxylase inhibition ([@B64])                N/A                                                        Adaptaquin ([@B62])                                                                                                 N/A                            N/A
  Others                       Baicalein ([@B4])                                    Naotaifang ([@B70]) Carvarol ([@B50])                                                                                                                              N/A                                                                                                HPL ([@B47]) PKC inhibitors-Bis III ([@B34])               N/A                                                                                                                 N/A                            HPL ([@B47])
                                                                                                                                                                                                                                                                                                                                                          1-HPPL ([@B79])                                                                                                                                                                                               
                               Vit E/α-tocopherol (αToc) ([@B76])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
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AD

:   Alzheimer's disease

CNS

:   Central nervous system

DFO

:   Deferoxamine

DFP

:   Deferiprone

Fer-1

:   ferrostatin-1

Gln

:   glutamine

GPX4

:   Glutathione peroxidase-4

GSH

:   glutathione

HD

:   Huntington's disease

HIF

:   hypoxia-inducible factor

ICH

:   intracerebral hemorrhage

Lip-1

:   liproxstatin-1

12/15-LOX

:   12/15-lipoxygenases

NCOA4

:   Nuclear receptor coactivator 4

PD

:   Parkinson's disease

PE

:   phosphatidylethanolamines

PHDs

:   prolyl-hydroxylases

PUFA

:   polyunsaturated fatty acid

ROS

:   reactive oxygen species

TBI

:   traumatic brain injury

TF

:   transferrin

TFR1

:   transferrin receptor 1.
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